Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
about
Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeysComparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.Economic impact of disease progression in follicular non-Hodgkin lymphoma.Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.Expressions of uroplakins in the mouse urinary bladder with cyclophosphamide-induced cystitis.Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.Cost-effectiveness of rituximab in follicular lymphoma.Trends and issues in oncology costs.Are high drug prices for hematologic malignancies justified? A critical analysis.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis.SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.Urinary uroplakin expression in cyclophosphamide-induced rat cystitis model.Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis.Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
P2860
Q28535043-378716B8-5DFF-49D6-8D61-3FD073F8DDC1Q35186372-E35E283C-F6A1-4C5D-B029-585563304036Q35205349-43B9E44B-830D-4736-9C0A-326C59C0F7EBQ35536558-2DFA2D27-BB55-469E-A369-E03B8C8FB9A9Q36210598-F02D8DF4-84A0-498B-A33E-AEAD738A9381Q37284704-B6D95BC6-3490-4EEA-B0DC-A60486DAAC75Q38011852-25017034-BAAB-46D8-8817-8FE89C549651Q38058840-0454E51C-AEAE-4C97-8481-D325B1B6878EQ38170426-68899D92-7230-4316-957C-B83EC99AFFF6Q38535347-7909E71E-1BBC-4D82-A510-5A283A341957Q38610648-D0B6477B-0124-4112-8F31-911A03824E2AQ42649795-0906F0F6-6595-4331-A2CD-F7FA729745B6Q43148758-3FEB254B-E6DF-45E3-98E1-159FBB03741FQ44908024-4F546627-0D58-49BF-A12E-95CDB2A2A673Q50892830-86A14DCB-8E46-4BD3-93F6-F7FC881D1046Q50977201-B6811E90-B9FB-491A-9FB6-141B4C2FAA38Q51336777-F139AC96-3055-49BB-9830-B02C8677FA50Q54261595-AA68BAD5-CCBC-4E9A-99F5-C5E4AD96DEEDQ58803120-2A536DA0-D79B-4748-BE4D-CEB0202D4321
P2860
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@ast
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@en
type
label
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@ast
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@en
prefLabel
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@ast
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@en
P2093
P2860
P1433
P1476
Economic evaluation of rituxim ...... r advanced follicular lymphoma
@en
P2093
Carolina Reyes
Deborah Lubeck
John Hornberger
Nancy Valente
P2860
P304
P356
10.1080/10428190701769665
P577
2008-02-01T00:00:00Z